Stock AnalizBrookdale Senior Living Inc. BKD
Hospital/Nursing Management · IPO 2005 · data as of November 13, 2026
Brookdale Senior Living Inc. (BKD) is a healthcare company listed in the US with a market value of about $2.2B. In the twelve months to September 30, 2026 it had revenue of $2.9B and net income of -$37M, a net margin of -1.3%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 151.0, 5-year revenue growth of -2% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 76% below the current price.
Score: 0.8 / 5
Checks passed
- ROE above 15%
- Positive free cash flow
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B | $3.2B | $3.1B | $3.0B | $2.8B | $2.8B | $3.5B | $4.1B | $4.5B | $4.7B | $5.0B |
| Net income | -$37M | -$263M | -$202M | -$189M | -$238M | -$99M | $82M | -$268M | -$528M | -$571M | -$404M |
| Free cash flow | $15M | $17M | -$35M | -$70M | -$194M | -$271M | $20M | -$88M | -$22M | $164M | $40M |
| EPS (diluted) | $-0.16 | $-1.12 | $-0.89 | $-0.84 | $-1.25 | $-0.54 | $0.44 | $-1.44 | $-2.82 | $-3.07 | $-2.18 |
| Net margin | -1.3% | -8.2% | -6.5% | -6.3% | -8.4% | -3.6% | 2.3% | -6.6% | -11.7% | -12.0% | -8.1% |
| ROIC | — | 0.2% | 0.7% | 0.3% | -0.8% | -3.7% | -1.6% | -0.8% | -11.7% | -3.9% | -0.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $16.17, 76% above the current price; targets range from $12.00 to $21.00; the consensus rating is “Strong buy”; expected EPS is $-0.62 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Brookdale Senior Living stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 76% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Brookdale Senior Living pay a dividend?
Not currently.
Is Brookdale Senior Living a good stock to buy?
We do not give buy or sell advice. Brookdale Senior Living scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.